Our science and innovation

Find out answers to key questions about clinical and real-world evidence studies on our smoke-free products.

The team led by PMI's Chief Medical Officer assesses the harm reduction potential of our better alternatives to smoking in controlled clinical studies and in the real world.

Quitting tobacco and nicotine products completely will always be the best option for smokers—but for those adults who would otherwise continue smoking, better alternatives exist.

Heated tobacco products and e-cigarettes (vapes) both deliver nicotine without burning tobacco.

Studies have shown PMI's Tobacco Heating System reduces average levels of harmful and potentially harmful constituents compared to cigarette smoke.

There’s a lot of confusion about vapes, e-cigarettes and heated tobacco products, so here are answers to common questions, along with links to more information

We’ve invested billions in research and development since 2008, employed hundreds of scientists, and created a range of better alternatives to smoking.

Shouldn’t adult smokers who don’t quit be able to choose less harmful alternatives to cigarettes? Reduced-risk products have the potential to present less risk to smokers who switch than continuing smoking.

From “What’s in cigarette smoke?” to “Are smoke-free products a better alternative?”, we answer seven key questions about cigarettes, smoking, tobacco, nicotine, and smoke-free products.

Many adult smokers are looking to replace cigarettes. Better alternatives to smoking include products that deliver nicotine by heating tobacco or an e-liquid, as well as nicotine pouches and snus.

E-cigarettes, both with and without nicotine, were found to have significantly lower biological responses associated with heart and lung diseases compared to cigarette smoke, a new PMI study finds.

Philip Morris International and Altria will make better choices available through socially responsible practices.

Information about the U.S. Food and Drug Administration’s (FDA’s) assessment of PMI's extensive scientific evidence package, and its July 7, 2020, decision to authorize IQOS as a modified risk tobacco product with reduced exposure information.

In a 2019 report, the WHO makes some statements that PMI does not agree with. We are separating the facts from the fiction.

Drawing on the results of an international survey, PMI's latest white paper highlights the public’s desire for both public and personal decision-making to be led by science.

Looking back at the progress we’ve made as the company transforms for good and accelerates toward a smoke-free future.